

## Data Sharing Statement

Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. DOI: 10.1056/NEJMoa2116596.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	The data availability of these trials is according to the criteria and process described on <a href="http://www.clinicalstudydatarequest.com">www.clinicalstudydatarequest.com</a> .
When will data availability begin?	With approved request
When will data availability end?	1 year of access; can obtain good cause extensions to continue research
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The data availability of these trials is according to the criteria and process described on <a href="http://www.clinicalstudydatarequest.com">www.clinicalstudydatarequest.com</a> .

For what type of analysis or purpose?	These requests are reviewed and approved by an independent review panel on the basis of scientific merit.
By what mechanism?	The data availability of these trials is according to the criteria and process described on <a href="http://www.clinicalstudydatarequest.com">www.clinicalstudydatarequest.com</a> .
Any other restrictions?	—
Additional information	—

This statement was posted on December 14, 2021, at NEJM.org.